The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Open accessAbstract
CONTEXT: Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. OBJECTIVE: To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. DESIGN: Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998. INTERVENTIONS: Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). MAIN OUTCOMES MEASURES: The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. RESULTS: On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10 000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10 000 person-years. CONCLUSIONS: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although hormone therapy is effective in treating hot flashes, its use is contraindicated for individuals initiating hormone therapy more than 10 years from menopause onset or older than 60 years, and with a history of breast cancer, uterine cancer, thromboembolic, or cardiovascular diseases.10,11,12”
From Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The WHI reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis during 5 years of treatment with conjugated equine estrogen and medroxyprogesterone acetate (Prempro®) [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The Woman’s Health Initiative (WHI) found that 5 years of HT (Prempro®) reduced the risk of clinical vertebral fractures and hip fractures by 34 % and other osteoporotic fractures by 23 % [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The Woman’s Health Initiative (WHI) found that 5 years of HT (Prempro®) reduced the risk of clinical vertebral fractures and hip fractures by 34 % and other osteoporotic fractures by 23 % [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Yet all of about 90 HIV vaccines that succeeded in animals failed in humans.55”
From The Flaws and Human Harms of Animal Experimentation (2015) · cites this paper as [55]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The increases were followed by equally pointed reductions within a few years, likely reflecting a depletion of prevalent cancers”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredIn the citing paper
“Data from the Women’s Health Initiative (WHI) shows several risks of menopausal hormone therapy among healthy postmenopausal women, including an excess risk of coronary heart disease, stroke, and breast cancer (151).”
From From mitochondria to sarcopenia: role of 17β-estradiol and testosterone (2023) · cites this paper as [151]
In the citing paper
“The recent data of the Women's Health Initiative Study show that the combination of Premarin and Provera (Prempro) causes a 26% increase in the risk of breast cancer at 5.2 yr of follow-up”
In the citing paper
“the recent results of the Women's Health Initiative Study (8) clearly indicate that this compound is not recommended for longterm use in normal women where the stimulatory progestational component could well be predominant.”
In the citing paper
“The most effective treatment of hot flushes is estrogen replacement therapy, but the Women’s Health Initiative Study raised questions about the long-term safety of this treatment (Rossouw et al., 2002).”
From Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes (2013) · cites this paper as Rossouw et al., 2002
In the citing paper
“Estrogen replacement therapy and hormone replacement therapy appear to have a neutral effect on BP, as illustrated by the following observations from 2 large randomized trials.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [212]
In the citing paper
“The Women’s Health Initiative, a randomized placebo-controlled trial, assessed the effect of estrogen-progestin replacement on outcomes in postmenopausal women211 and found that at 5.2 years hormone replacement therapy produced only a small increase (1.5 mm Hg) in SBP compared with placebo.212”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [212]
In the citing paper
“Estrogen has also been associated with increased risk of “unusual site” thromboses, as well as arterial thrombosis.”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [97]
In the citing paper
“That same year, data from the Women’s Health Initiative randomized clinical trial showed an increased risk of MI and cardiovascular death in women on MHT (HR 1.29, 95% CI, 1.02–1.63) [97].”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [97]
In the citing paper
“For example, the hypothesis that the effect of hormone replacement therapy (HRT) on coronary heart disease (CHD) might differ depending on the timing of its use (in relation to menopausal status) was not raised until after results from RCTs were published.47,48”
From Triangulation in aetiological epidemiology (2017) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Calle, E. E., Heath Jr., C. W., Coates, R. J., Liff, J. M., Franceschi, S., Talamini, R., Chantarakul, N., Koetsawang, S., Rachawat, D., Morabia, A., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08233-0 · Cited by 2,450
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,921
Stampfer, M. J., & Colditz, G. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90006-p · Cited by 1,611
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Flagged first, then by citations
Research works printed but not linked: 6
- [5]5. Rijpkema AH, van der Sanden AA, Ruijs AH. Ef- fects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review. Ma- turitas. 1990;12:259-285.
- [18]18. Cox DR. Regression analysis and life tables. J R Stat Soc. 1972;34:187-220.
- [23]23. Writing Group for the PEPI Trial. Effects of estro- gen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995; 273:199-208.
- [25]25. Schulman SP, Thiemann DR, Ouyang P, et al. Ef- fects of acute hormone therapy on recurrent ische- mia in postmenopausal women with unstable an- gina. J Am Coll Cardiol. 2002;39:231-237.
- [29]29. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind controlled trial. Ann Intern Med. 2001; 135:939-953.
- [43]43. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275:1389- 1396.
Cited by
Sorted by citations
Items 101–200 of 1,145
Cauley, J. A. (2003) · JAMA · doi:10.1001/jama.290.13.1729 · Cited by 1,229
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Sambrook, P. N., & Cooper, C. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,201
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Nelson, L. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0808697 · Cited by 1,189
Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women
Wassertheil-Smoller, S. W., Hendrix, S. L., Limacher, M. C., HEISS, G. M., Kooperberg, C. L., Baird, A. E., Kotchen, T. A., Curb, J. D., Black, H. R., Rossouw, J. E., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2673 · Cited by 1,160
Smith, G. C. S., & Pell, J. P. (2003) · BMJ · doi:10.1136/bmj.327.7429.1459 · Cited by 1,155
Jemal, A., Clegg, L. X., Ward, E., Ries, L. A. G., Wu, X., Jamison, P. M., Wingo, P. A., Howe, H. L., Anderson, R. N., & Edwards, B. K. (2004) · Cancer · doi:10.1002/cncr.20288 · Cited by 1,141
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Triangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129
Lei, S., Zheng, R., Zhang, S., Wang, S., Chen, R., Sun, K., Zeng, H., Zhou, J., & Wei, W. (2021) · 癌症：英文版 · doi:10.1002/cac2.12207 · Cited by 1,210
Hayat, M. J., Howlader, N., Reichman, M. E., & Edwards, B. K. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-20 · Cited by 1,097
Howard, B. V., Van Horn, L., Hsia, J., Manson, J. E., Stefanick, M. L., Wassertheil-Smoller, S., Kuller, L. H., LaCroix, A. Z., Langer, R. D., Lasser, N. L., et al. (2006) · JAMA · doi:10.1001/jama.295.6.655 · Cited by 1,091
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris, E. S., Chen, Y.-T., Abbott, T. A., Barrett-Connor, E. L., Miller, P. D., Wehren, L. E., & Berger, M. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1108 · Cited by 1,109
Identifying and Avoiding Bias in Research
Pannucci, C. J., & Wilkins, E. G. (2010) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e3181de24bc · Cited by 1,079
Cardiovascular Disease in Women
Garcia, M. C., Mulvagh, S. L., Merz, C. N. B., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,140
Progress in evidence-based medicine: a quarter century on
Djulbegovic, B., & Guyatt, G. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31592-6 · Cited by 1,022
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Sex/Gender Differences in Cardiovascular Disease Prevention: What a Difference a Decade Makes
Mosca, L., Barrett-Connor, E., & Kass Wenger, N. (2011) · Circulation · doi:10.1161/circulationaha.110.968792 · Cited by 1,045
Sex Differences in Stroke Epidemiology
Appelros, P., Stegmayr, B., & Terént, A. (2009) · Stroke · doi:10.1161/strokeaha.108.540781 · Cited by 1,076
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,050
Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E., Green, L. A., Hand, M. M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.002 · Cited by 1,019
Leng, S. X., Chen, X., & Mao, G. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s45300 · Cited by 1,066
In vivo effects of bisphenol A in laboratory rodent studies
Richter, C. A., Birnbaum, L. S., Farabollini, F., Newbold, R. R., Rubin, B. S., Talsness, C. E., Vandenbergh, J. G., Walser-Kuntz, D. R., & vom Saal, F. S. (2007) · Reproductive Toxicology · doi:10.1016/j.reprotox.2007.06.004 · Cited by 1,147
Rehm, J., Room, R., Graham, K., Monteiro, M., Gmel, G., & Sempos, C. T. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00467.x · Cited by 995
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Risk factors for lung cancer worldwide
Malhotra, J. D., Malvezzi, M., Negri, E., Vecchia, C. L., & Boffetta, P. (2016) · European Respiratory Journal · doi:10.1183/13993003.00359-2016 · Cited by 1,050
National Use of Postmenopausal Hormone Therapy
Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004) · JAMA · doi:10.1001/jama.291.1.47 · Cited by 984
The Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 981
Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer
Wactawski‐Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O’Sullivan, M. J., Margolis, K. L., Ockene, J. K., Phillips, L. S., Pottern, L. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055222 · Cited by 980
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 984
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J. R., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 969
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R., Panay, N., & Fenton, A. J. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 968
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 968
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Bushnell, C., McCullough, L. D., Awad, I. A., Chireau, M. V., Fedder, W. N., Furie, K. L., Howard, V. J., Lichtman, J. H., Lisabeth, L. D., Piña, I. L., et al. (2014) · Stroke · doi:10.1161/01.str.0000442009.06663.48 · Cited by 941
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women
Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L. S., Stefanick, M. L., Lane, D. S., Hays-Grudo, J., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2663 · Cited by 939
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L. J., Appel, L. J., Benjamin, E. J., Berra, K. A., Chandra‐Strobos, N., Fabunmi, R. P., Grady, D. G., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000114834.85476.81 · Cited by 918
Marco, M. L., Sanders, M. E., Gänzle, M., Arrieta, M. C., Cotter, P. D., De Vuyst, L., Hill, C., Holzapfel, W., Lebeer, S., Merenstein, D., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00390-5 · Cited by 937
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Becker, K. J., Furberg, C. D., Gorelick, P. B., Hádemenos, G. J., Hill, M., Howard, G., Howard, V. J., Jacobs, B. S., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 902
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Just one question: If one question works, why ask several?
Bowling, A. (2005) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2004.021204 · Cited by 892
Abedin, M., Tintut, Y., & Demer, L. L. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000133194.94939.42 · Cited by 865
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women
Canonico, M., Oger, E., Plu‐Bureau, G., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. ‐., Wahl, D. G., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 867
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz‐Flores, S., Dent, S. F., Kondapalli, L., Ky, B., Okwuosa, T. M., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 883
Eastell, R., O’Neill, T. W., Hofbauer, L. C., Langdahl, B. L., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 877
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Risk for New Onset of Depression During the Menopausal Transition
Cohen, L. S., Soares, C. N., Vitonis, A. F., Otto, M. W., & Harlow, B. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.385 · Cited by 852
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 832
Pharmacology of estrogens and progestogens: influence of different routes of administration
Kühl, H. (2005) · Climacteric · doi:10.1080/13697130500148875 · Cited by 864
Prentice, R. L., Caan, B., Chlebowski, R. T., Patterson, R., Kuller, L. H., Ockene, J. K., Margolis, K. L., Limacher, M. C., Manson, J. E., Parker, L. M., et al. (2006) · JAMA · doi:10.1001/jama.295.6.629 · Cited by 828
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J. E., Cooper, A., Cooper, C. C., Gittoes, N. J. L., Gregson, C. L., Harvey, N. C., Hope, S., Kanis, J. А., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 865
The Critical Role of Metabolic Pathways in Aging
Barzilai, N., Huffman, D. M., Muzumdar, R. H., & Bartke, A. (2012) · Diabetes · doi:10.2337/db11-1300 · Cited by 803
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.009 · Cited by 826
Clinical Use of Bone Densitometry
Cummings, S. R., Bates, D. W., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 856
International patterns and trends in endometrial cancer incidence, 1978-2013.
Lortet-Tieulent, J., Ferlay, J., Bray, F., & Jemal, A. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx214 · Cited by 760
International Variation in Female Breast Cancer Incidence and Mortality Rates
Desantis, C. E., Bray, F., Ferlay, J., Lortet‐Tieulent, J., Anderson, B. O., & Jemal, A. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0535 · Cited by 829
Prevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
Espeland, M. A. (2004) · JAMA · doi:10.1001/jama.291.24.2959 · Cited by 794
Calle, E. E., & Thun, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207751 · Cited by 805
Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update
Mosca, L. J., Benjamin, E. J., Berra, K. A., Bezanson, J. L., Dolor, R. J., Lloyd‐Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.005 · Cited by 795
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
The North American Menopause Society (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31824b970a · Cited by 787
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823c074e · Cited by 795
Estrogen synthesis and signaling pathways during aging: from periphery to brain
Cui, J., Shen, Y., & Li, R. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.007 · Cited by 785
Amsterdam, E. A., WENGER, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H. M., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.016 · Cited by 782
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. А., Burlet, N., Cooper, C. C., Delmas, P. D., Reginster, J., Borgström, F., & Rizzoli, R. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 796
Evidence for Health Decision Making — Beyond Randomized, Controlled Trials
Frieden, T. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1614394 · Cited by 770
The epidemiology of osteoporosis
Clynes, M. A., Harvey, N. C., Curtis, E. M., Fuggle, N. R., Dennison, E. M., & Cooper, C. C. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa005 · Cited by 812
Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L. J., Banka, C. L., Benjamin, E. J., Berra, K. A., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 753
Thacher, T. D., & Clarke, B. L. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0567 · Cited by 775
Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L. S., Eiken, P., Mosekilde, L., Køber, L., & Jensen, J. B. (2012) · BMJ · doi:10.1136/bmj.e6409 · Cited by 753
Atsma, F., Bartelink, M.-L. E. L., Grobbee, D. E., & van der Schouw, Y. T. (2006) · Menopause · doi:10.1097/01.gme.0000218683.97338.ea · Cited by 744
Is job strain a major source of cardiovascular disease risk?
Belkic, K. L., Landsbergis, P. A., Schnall, P. L., & Baker, D. B. (2004) · Scandinavian Journal of Work Environment & Health · doi:10.5271/sjweh.769 · Cited by 761
Goldstein, L. B., Bushnell, C., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · Cited by 745
Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., & Day, N. (2007) · Circulation · doi:10.1161/circulationaha.107.719005 · Cited by 743
Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R. A., Huber, J. C., Pasqualini, J. R., Schweppe, K.-W., & Thijssen, J. H. H. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.014 · Cited by 741
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
Nelson, H. D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60346-3 · Cited by 728
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 736
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 758
Drug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 736
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 720
Estrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711
Youlden, D. R., Cramb, S. M., Dunn, N., Muller, J., Pyke, C., & Baade, P. D. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.02.007 · Cited by 709
Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests
Hoffmann, T., & Mar, C. D. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6016 · Cited by 720
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Scarabin, P., Oger, E., & Plu‐Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 704
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
DeCarli, C., Massaro, J., Harvey, D., Hald, J., Tullberg, M., Au, R., Beiser, A., D’Agostino, R., & Wolf, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.004 · Cited by 680
Androgens and Cardiovascular Disease
Liu, P. Y., Death, A. K., & Handelsman, D. J. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0005 · Cited by 695
Men: good health and high mortality. Sex differences in health and aging
Oksuzyan, A., Juel, K., Vaupel, J. W., & Christensen, K. (2008) · Aging Clinical and Experimental Research · doi:10.1007/bf03324754 · Cited by 692
Metadata
- Authors
- Writing Group for the Women's Health Initiative Investigators
- Affiliations
- National Heart, Lung, and Blood Institute (US)
- Corresponding author
- Writing Group for the Women's Health Initiative Investigators
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-17
- Volume
- 288
- Issue
- 3
- Pages
- 321-333
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- 1538-3598
- OpenAlex
- W1593442063
- Cited by
- 15,889
- References
- 54
- Citations by year
- 2026: 283 · 2025: 348 · 2024: 342 · 2023: 365 · 2022: 459 · 2021: 465 · 2020: 452 · 2019: 453 · 2018: 455 · 2017: 452 · 2016: 486 · 2015: 572 · 2014: 546 · 2013: 688 · 2012: 713
- FWCI
- 647.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Nursing › Nutrition and Dietetics › Phytoestrogen effects and research
- Keywords
- estrogen plus progestin, conjugated equine estrogens, medroxyprogesterone acetate, postmenopausal women, hormone replacement therapy, coronary artery disease, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, mortality, benefits and risks, Women's Health Initiative, early trial termination, primary prevention
- MeSH terms
- Aged, Breast Neoplasms, Coronary Disease, Estrogens, Conjugated (USP), Female, Humans, Middle Aged, Myocardial Infarction, Pulmonary Embolism, Risk, Thrombosis, Colorectal Neoplasms, Estrogen Replacement Therapy, Proportional Hazards Models, Survival Analysis, Endometrial Neoplasms, Treatment Outcome, Medroxyprogesterone Acetate, Postmenopause, Stroke, Clinical Trials Data Monitoring Committees, Progesterone Congeners, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
